DexCom Reports Strong Q2 Earnings and Outlines Growth Strategy
DexCom reported second-quarter revenue of $1.31 billion in July 2026, a 13% increase year-over-year driven by strong demand for its continuous glucose monitoring (CGM) systems, new customer starts, expanded reimbursement access, and market share gains. U.S. revenue rose 11%, while international sales grew 19%. The company reaffirmed its full-year guidance with projected revenue between $5.18 billion to $5.25 billion and an adjusted EBITDA margin of 31.5% to 32%. Gross margins improved significantly, rising from 60.1% in the prior year to 64.1%, while net income increased by 46% to $269.1 million. DexCom is expanding access for non-insulin Type 2 diabetes patients and submitted positive results from its CONNECT trial to CMS, supporting broader coverage efforts. The company also highlighted product momentum with the rollout of G7 15-day sensors, a new acquisition (Nutrisense), and plans for a smaller multi-analyte sensor—G8—to launch in late 2027 or early 2028.
Topics: CGM_demand international_expansion product_launches revenue_growth